Psychedelic Inequality: From Clinical Trials to the American Health Care System

On April 18, 2026, President Trump signed an executive order directing the Food and Drug Administration to accelerate the development and review of psychedelic therapeutics, including psilocybin, MDMA, and Ibogaine. The order framed psychedelic medicines as a central part of solving the United States mental health crisis. Yet, it said nothing about ensuring access to these treatments once they are fully approved.

In 2021, I published a Public Health Post article on psychedelic public health, in which I raised concerns that “medicalization alone will likely only distribute the benefits of psychedelics among those with the privilege to access them.” At the time, these concerns were theoretical. Today, they are a reality. As psychedelics move from clinical trials to clinics, the test of their impact on the mental health crisis should be measured by their ability to reach the population with the greatest burden of disease.  

Exclusion starts during clinical trials. A substantial body of literature shows that the research behind the development of these therapies tends to leave out those with complex psychiatric conditions, heavy substance use, psychosis, or unstable living situations. Researchers usually exclude these patients for safety reasons, but doing so creates a fundamental implementation problem once the treatment reaches the clinic.

The U.S. health care system is not ready to implement this type of therapy.

The secondary exclusion is cost. Current estimates for a full course of psychedelic treatment range from thousands to tens of thousands of dollars out-of-pocket. The high price tag for psychedelic medicines does not come from the drugs, but the system that supports their delivery. In this kind of treatment, a patient takes the medicine in a clinic and is supported by trained clinicians before, during, and after the dose. That makes it labor-intensive: preparation sessions, hours of supervised dosing, follow-up “integration” therapy, specially trained facilitators, and dedicated clinical space. The price is pushed higher still by monopoly pricing on patented compounds, company-controlled protocols, and federally mandated safety overhead.

The U.S. health care system is not ready to implement this type of therapy. There are no permanent standardized billing codes for the multi-step model these therapies follow, and no federally established licensure pathways for the therapists who provide it. On top of that, the country already faces a broad shortage of mental health workers, which leaves few clinicians free to take on the demanding and expensive training these treatments require, creating further barriers for patients.  

Some states are not waiting for federal guidance or insurance coverage. Oregon already runs a regulated psilocybin program, but a single session costs between $1,000 and $3,000, paid entirely by the patient. At that price, the treatment is out of reach for most people, and only a handful of states even offer it. New Mexico is exploring group psychedelic-assisted therapy models to lower cost, but even that model likely creates a two-tiered system of treatment. Those who want and can pay for individualized care will get it. Those who can’t pay will not. New Mexico legislated an equity fund to address this problem, funded by oil and gas revenues unique to the state. This is a commendable achievement, but one that depends on a fiscal foundation most states lack without major reallocation of funds or a new tax.

For most Americans, access to these therapies will come down to insurance coverage. The problem is that the people who suffer from complex mental illness in the U.S. are often uninsured or underinsured, or they rely on Medicaid.

Once FDA approval is achieved, Medicaid coverage will be mandatory under federal law; however, coverage alone does not guarantee meaningful access. In practice, prior authorization, limited provider participation, and low reimbursement will keep psychedelic therapies out of reach for the people who need them most. This has already played out with Esketamine, marketed as Spravato, which won FDA approval in 2019 for treatment-resistant depression. On paper, it is covered by Medicaid. Yet access remains concentrated among wealthier, privately insured patients.  

Instead of transforming mental health treatment, psychedelic medicine risks reproducing the inequities it claims to disrupt.

From a public health perspective, as demand for psychedelics grows, those unable to afford legal access will turn to unregulated and unsafe drug markets. The consequence is that psychedelic drug-related harms will increase from exposure to unlicensed practitioners operating outside the oversight of an institution, unsupervised use, fentanyl contamination, and increasingly powerful synthetic formulations (known as syndelics) marketed as classic psychedelic drugs. The result is a system in which the people least able to access regulated care assume the greatest safety and legal risks.

The most important fix is also the easiest one: federally funded trials should be required to enroll participants who carry the heaviest burden of mental illness. This will close the evidence gap before it hardens into standard practice. From there, clearer insurance billing rules, expanding state Medicaid 1115 waivers, real enforcement of mental health parity, and FDA approvals tied to concrete affordability commitments will help ensure access is driven by need, not the ability to pay.

The psychedelic medicalization movement spent decades fighting for legitimacy. That era is ending. The next test is about access. If psychedelic medicine is implemented through exclusionary trials, high-cost delivery, thin insurance coverage, and uneven state systems, those with the greatest need will be excluded or pushed toward less safe and more legally vulnerable pathways to care. Instead of transforming mental health treatment, psychedelic medicine risks reproducing the inequities it claims to disrupt.

The views expressed here are the author’s own and do not necessarily represent the views of Public Health Post or Boston University School of Public Health.